Isolated Abducens Nerve Palsy Following Pembrolizumab

Pembrolizumab is a checkpoint inhibitor targeting the programmed cell death 1 receptor of lymphocytes and is used in the treatment of solid tumours including melanoma. The authors report a 64-year-old man treated with pembrolizumab for stage IV cutaneous melanoma (primary cutaneous melanoma of the r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuroophthalmology
Autors principals: Jaben, Korey A., Francis, Jasmine H., Shoushtari, Alexander N., Abramson, David H.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Case Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7202430/
https://ncbi.nlm.nih.gov/pubmed/32395170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/01658107.2019.1566385
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars